CorMedix Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CorMedix Inc (CRMD)
The CorMedix share price today is 8.420, view NASDAQ CRMD stock exchange data. Track the latest CorMedix share price with real-time updates on CRMD stock performance including market cap, day range, 52-week range and dividend yield. Access CRMD charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.140
8.530
52 wk Range
6.125
14.960
CRMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.1408.530
52 wk Range
6.12514.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRMD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
15.000
Upside
+78.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Form DEF 14A CorMedix Inc For: 25 June
- Investing.com
- Form 13G CorMedix Inc. For: 12 June
- Investing.com
- CorMedix Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form DEF 14A CorMedix Inc For: 25 June
- Investing.com
- Form 13G CorMedix Inc. For: 12 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15.000
(+78.15% Upside)
CorMedix Inc SWOT Analysis
Strategic Acquisition | CorMedix's $300M acquisition of Melinta Therapeutics promises portfolio diversification and near-term EPS accretion, reshaping its market position |
Financial Projections | Explore CorMedix's ambitious FY2025 guidance, projecting revenues of $305M-$330M and EBITDA of $150M-$170M, signaling strong growth potential |
DefenCath's Momentum | Delve into DefenCath's Q2 2025 sales of $39M and its potential expansion into the TPN market, highlighting CorMedix's focus on product development |
Analyst Outlook | Citizens Bank sets a $22 price target for CRMD, labeling it "MARKET OUTPERFORM" and underscoring the stock's potential upside |
CorMedix Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue surged 226% YoY to $127.4M, beating estimates of $105M; EPS of $0.43 missed forecast of $0.45 by 4.44%
- Strong DefenCath demand and Melinta acquisition drove growth; adjusted EBITDA jumped 197% to $70M from $23.6M YoY
- Full-year 2026 revenue guidance raised to $325M-$345M from $300M-$320M; EBITDA guidance increased to $115M-$135M
- Stock surged 13.46% to $8.51 in premarket trading following earnings beat and raised guidance
- Key risks include DefenCath reimbursement transitions, Melinta integration challenges, and potential regulatory headwinds
Last Updated: 14-05-2026, 06:46 pm
Read Full TranscriptEarnings
Latest Release
14-05-2026
EPS / Forecast
0.43 / 0.45
Revenue / Forecast
127.43M / 105.02M
Compare CRMD to Peers and Sector
Metrics to compare | CRMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.7x | −1.5x | −0.4x | |
PEG Ratio | 0.01 | −0.24 | 0.00 | |
Price/Book | 1.5x | 1.3x | 2.6x | |
Price / LTM Sales | 1.7x | 1.4x | 3.1x | |
Upside (Analyst Target) | 80.9% | 153.2% | 50.8% | |
Fair Value Upside | Unlock | 10.1% | 7.8% | Unlock |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the CorMedix (CRMD) Share Price Today?
The CorMedix share price today is 8.420.
What is the current CorMedix (CRMD) share price and day range?
As of 17-07-2026, the CorMedix share price is 8.420, with a previous close of 8.290. The share price has ranged from 8.140 to 8.530 today, while the 52-week range spans from 6.125 to 14.960.
What Is the CorMedix Market Cap?
As of today, CorMedix market cap is 665.270M.
What Is the CorMedix (CRMD) Share Price Target?
The average 12-month share price target for CorMedix is 15.000, with a high estimate of 19 and a low estimate of 13. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +78.15% Upside potential.
What Is CorMedix's Earnings Per Share (TTM)?
The CorMedix EPS (TTM) is 2.120.
When Is the Next CorMedix Earnings Date?
CorMedix will release its next earnings report on 06-08-2026.
From a Technical Analysis Perspective, Is CRMD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Stock Exchange Does CorMedix Trade On?
CorMedix is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for CorMedix?
The stock symbol for CorMedix is "CRMD."
How Many Times Has CorMedix Stock Split?
CorMedix has split 1 times.
How Many Employees Does CorMedix Have?
CorMedix has 191 employees.
What Is the CRMD Premarket Price?
CRMD's last pre-market stock price is 8.180. The pre-market share volume is 2,350.000, and the stock has changed by -0.110, or -1.330%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.